Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cash from Investing Activities (2016 - 2024)

Historic Cash from Investing Activities for NovaBay Pharmaceuticals (NBY) over the last 15 years, with Q4 2024 value amounting to $1.1 million.

  • NovaBay Pharmaceuticals' Cash from Investing Activities rose 3563333.33% to $1.1 million in Q4 2024 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 2142000.0%. This contributed to the annual value of $1.1 million for FY2024, which is 570000.0% up from last year.
  • As of Q4 2024, NovaBay Pharmaceuticals' Cash from Investing Activities stood at $1.1 million, which was up 3563333.33% from -$2000.0 recorded in Q1 2024.
  • In the past 5 years, NovaBay Pharmaceuticals' Cash from Investing Activities registered a high of $1.1 million during Q4 2024, and its lowest value of -$12.0 million during Q4 2021.
  • For the 5-year period, NovaBay Pharmaceuticals' Cash from Investing Activities averaged around -$742533.3, with its median value being -$8000.0 (2022).
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Cash from Investing Activities plummeted by 5704761.9% in 2021, and later surged by 3563333.33% in 2024.
  • NovaBay Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$21000.0 in 2020, then crashed by 57047.62% to -$12.0 million in 2021, then soared by 99.33% to -$80000.0 in 2022, then soared by 96.25% to -$3000.0 in 2023, then soared by 35633.33% to $1.1 million in 2024.
  • Its last three reported values are $1.1 million in Q4 2024, -$2000.0 for Q1 2024, and -$3000.0 during Q4 2023.